| Manuel Eduardo Sanchez Casalongue, MD/PHD | |
|
2040 Ogden Ave Ste 115, Aurora, IL 60504-7205 | |
| (630) 585-0200 | |
| (630) 585-7396 |
| Full Name | Manuel Eduardo Sanchez Casalongue |
|---|---|
| Gender | Male |
| Speciality | General Surgery |
| Experience | 8 Years |
| Location | 2040 Ogden Ave Ste 115, Aurora, Illinois |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1700232501 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Copley Memorial Hospital | Aurora, IL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Rush-copley Medical Group Nfp | 7618864877 | 108 |
News Archive
PRI's "The World" recently spoke with Matt Ellingson, director of Program Development at Samaritan's Purse, an international Christian relief organization, who was part of a mission to North Korea this month during which five U.S.-based, non-governmental organizations were allowed to send observers to the country to monitor delivery of aid to areas affected by severe floods this past summer. The group "came away concerned about widespread malnutrition and starvation in North Korea" and "is now calling for an urgent humanitarian intervention," "The World" reports.
For decades most cancers have been treated with a core standard of treatments that include surgery, radiation, and chemotherapy. Now, immunotherapy—a type of treatment that harnesses the patient's immune system to combat the disease—represents the future of cancer treatment, with its efficacy being demonstrated in even the most aggressive types of cancer.
Debiopharm Group, SA (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, today presented the 'Debiopharm Life Sciences Award' to Dr Lluis Quintana-Murci from the Institut Pasteur in France, for his outstanding innovative research in the emerging field of evolutionary genetics of infection.
Researchers at the University of North Carolina at Chapel Hill School of Medicine, after isolating normal stem cells that form the developing placenta, have given them the same properties of stem cells associated with an aggressive type of breast cancer.
› Verified 3 days ago
| Entity Name | Rush-copley Medical Group Nfp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093075848 PECOS PAC ID: 7618864877 Enrollment ID: O20040310001029 |
News Archive
PRI's "The World" recently spoke with Matt Ellingson, director of Program Development at Samaritan's Purse, an international Christian relief organization, who was part of a mission to North Korea this month during which five U.S.-based, non-governmental organizations were allowed to send observers to the country to monitor delivery of aid to areas affected by severe floods this past summer. The group "came away concerned about widespread malnutrition and starvation in North Korea" and "is now calling for an urgent humanitarian intervention," "The World" reports.
For decades most cancers have been treated with a core standard of treatments that include surgery, radiation, and chemotherapy. Now, immunotherapy—a type of treatment that harnesses the patient's immune system to combat the disease—represents the future of cancer treatment, with its efficacy being demonstrated in even the most aggressive types of cancer.
Debiopharm Group, SA (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, today presented the 'Debiopharm Life Sciences Award' to Dr Lluis Quintana-Murci from the Institut Pasteur in France, for his outstanding innovative research in the emerging field of evolutionary genetics of infection.
Researchers at the University of North Carolina at Chapel Hill School of Medicine, after isolating normal stem cells that form the developing placenta, have given them the same properties of stem cells associated with an aggressive type of breast cancer.
› Verified 3 days ago
| Entity Name | Copley Memorial Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1619466034 PECOS PAC ID: 4587656921 Enrollment ID: O20180530001537 |
News Archive
PRI's "The World" recently spoke with Matt Ellingson, director of Program Development at Samaritan's Purse, an international Christian relief organization, who was part of a mission to North Korea this month during which five U.S.-based, non-governmental organizations were allowed to send observers to the country to monitor delivery of aid to areas affected by severe floods this past summer. The group "came away concerned about widespread malnutrition and starvation in North Korea" and "is now calling for an urgent humanitarian intervention," "The World" reports.
For decades most cancers have been treated with a core standard of treatments that include surgery, radiation, and chemotherapy. Now, immunotherapy—a type of treatment that harnesses the patient's immune system to combat the disease—represents the future of cancer treatment, with its efficacy being demonstrated in even the most aggressive types of cancer.
Debiopharm Group, SA (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, today presented the 'Debiopharm Life Sciences Award' to Dr Lluis Quintana-Murci from the Institut Pasteur in France, for his outstanding innovative research in the emerging field of evolutionary genetics of infection.
Researchers at the University of North Carolina at Chapel Hill School of Medicine, after isolating normal stem cells that form the developing placenta, have given them the same properties of stem cells associated with an aggressive type of breast cancer.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Manuel Eduardo Sanchez Casalongue, MD/PHD 2040 Ogden Ave Ste 115, Aurora, IL 60504-7205 Ph: (630) 585-0200 | Manuel Eduardo Sanchez Casalongue, MD/PHD 2040 Ogden Ave Ste 115, Aurora, IL 60504-7205 Ph: (630) 585-0200 |
News Archive
PRI's "The World" recently spoke with Matt Ellingson, director of Program Development at Samaritan's Purse, an international Christian relief organization, who was part of a mission to North Korea this month during which five U.S.-based, non-governmental organizations were allowed to send observers to the country to monitor delivery of aid to areas affected by severe floods this past summer. The group "came away concerned about widespread malnutrition and starvation in North Korea" and "is now calling for an urgent humanitarian intervention," "The World" reports.
For decades most cancers have been treated with a core standard of treatments that include surgery, radiation, and chemotherapy. Now, immunotherapy—a type of treatment that harnesses the patient's immune system to combat the disease—represents the future of cancer treatment, with its efficacy being demonstrated in even the most aggressive types of cancer.
Debiopharm Group, SA (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, today presented the 'Debiopharm Life Sciences Award' to Dr Lluis Quintana-Murci from the Institut Pasteur in France, for his outstanding innovative research in the emerging field of evolutionary genetics of infection.
Researchers at the University of North Carolina at Chapel Hill School of Medicine, after isolating normal stem cells that form the developing placenta, have given them the same properties of stem cells associated with an aggressive type of breast cancer.
› Verified 3 days ago
Nancy E Whereatt, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 1221 N Highland Ave, Aurora, IL 60506 Phone: 630-859-8700 | |
Dr. Daniel Katz, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 2040 Ogden Ave Ste 304, Aurora, IL 60504 Phone: 630-898-3727 | |
Craig L Weinstein, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 2040 Ogden Ave, Ste. 115, Aurora, IL 60504 Phone: 630-585-0200 Fax: 630-585-7396 | |
Mr. Donald Paul Prentiss Jr., M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 1221 N Highland Ave, Aurora, IL 60506 Phone: 630-859-8700 | |
Tedi Vlahu, Surgery Medicare: Accepting Medicare Assignments Practice Location: 1325 N Highland Ave, Aurora, IL 60506 Phone: 630-801-5700 | |
Dr. Gregory A Spitz, M.D., F.A.C.S Surgery Medicare: Accepting Medicare Assignments Practice Location: 1256 Waterford Dr, Suite 130, Aurora, IL 60504 Phone: 630-820-2727 Fax: 630-820-7427 | |
Franklin E Baumann, MD Surgery Medicare: Not Enrolled in Medicare Practice Location: 1221 N Highland Ave, Aurora, IL 60506 Phone: 630-859-8700 Fax: 630-264-8858 |